Suppr超能文献

在有症状的不可逆性牙髓炎患者中,阿替卡因比利多卡因更具优势吗?一项系统评价与荟萃分析。

Does Articaine Provide an Advantage over Lidocaine in Patients with Symptomatic Irreversible Pulpitis? A Systematic Review and Meta-analysis.

作者信息

Kung Jason, McDonagh Marian, Sedgley Christine M

机构信息

Department of Endodontology, School of Dentistry, Oregon Health and Science University, Portland, Oregon.

Pacific Northwest Evidence-based Practice Center, Oregon Health and Science University, Portland, Oregon.

出版信息

J Endod. 2015 Nov;41(11):1784-94. doi: 10.1016/j.joen.2015.07.001. Epub 2015 Aug 17.

Abstract

INTRODUCTION

Achieving profound pulpal anesthesia can be difficult in patients with symptomatic irreversible pulpitis. This study provides a systematic review and meta-analysis to address the population, intervention, comparison, outcome (PICO) question: in adults with symptomatic irreversible pulpitis who are undergoing endodontic treatment, what is the comparative efficacy of articaine compared with lidocaine in reducing pain and incidence of adverse events?

METHODS

A protocol was prepared and registered on PROSPERO. Electronic searches were conducted in MEDLINE, Scopus, Cochrane Library, and ClinicalTrials.gov by using strict inclusion and exclusion criteria. Two independent reviewers assessed eligibility for inclusion and quality. Weighted anesthesia success rates and 95% confidence intervals (CIs) were estimated and compared by using a random-effects model.

RESULTS

Two hundred seventy-five studies were initially identified from the search; 10 double-blind, randomized clinical trials met the inclusion criteria. For combined studies, articaine was more likely than lidocaine to achieve successful anesthesia (odds ratio [OR], 2.21; 95% CI, 1.41-3.47; P = .0006; I(2) = 40%). Maxillary infiltration subgroup analysis showed no significant difference between articaine and lidocaine (OR, 3.99; 95% CI, 0.50-31.62; P = .19; I(2) = 59%). For combined mandibular anesthesia studies articaine was superior to lidocaine (OR, 2.20; 95% CI, 1.40-3.44; P = .0006; I(2) = 30%), with further subgroup analysis showing no difference for mandibular block anesthesia (OR, 1.44; 95% CI, 0.87-2.38; P = .16; I(2) = 0%). When used for supplemental infiltration after successful mandibular block anesthesia, articaine was significantly more effective than lidocaine (OR, 3.55; 95% CI, 1.97-6.39; P < .0001; I(2) = 9%). There were no reports of adverse events.

CONCLUSIONS

This systematic review of double-blind, randomized clinical trials provides level 1 evidence to support the use of articaine for patients with symptomatic irreversible pulpitis. There is a significant advantage to using articaine over lidocaine for supplementary infiltration after mandibular block anesthesia but no advantage when used for mandibular block anesthesia alone or for maxillary infiltration.

摘要

引言

对于有症状的不可逆性牙髓炎患者,实现深度牙髓麻醉可能具有挑战性。本研究进行了一项系统评价和荟萃分析,以解决人群、干预措施、对照、结局(PICO)问题:在接受牙髓治疗的有症状不可逆性牙髓炎成年患者中,与利多卡因相比,阿替卡因在减轻疼痛和不良事件发生率方面的比较疗效如何?

方法

制定了一项方案并在国际前瞻性系统评价注册库(PROSPERO)上进行了注册。通过严格的纳入和排除标准,在医学文献数据库(MEDLINE)、Scopus、考克兰图书馆和美国国立医学图书馆临床试验注册库(ClinicalTrials.gov)中进行了电子检索。两名独立的评审员评估纳入资格和质量。使用随机效应模型估计并比较加权麻醉成功率和95%置信区间(CI)。

结果

通过检索最初识别出275项研究;10项双盲随机临床试验符合纳入标准。对于合并研究,阿替卡因比利多卡因更有可能实现成功麻醉(优势比[OR],2.21;95%CI,1.41 - 3.47;P = 0.0006;I² = 40%)。上颌浸润亚组分析显示阿替卡因和利多卡因之间无显著差异(OR,3.99;95%CI,0.50 - 31.62;P = 0.19;I² = 59%)。对于合并的下颌麻醉研究,阿替卡因优于利多卡因(OR,2.20;95%CI,1.40 - 3.44;P = 0.0006;I² = 30%),进一步的亚组分析显示下颌阻滞麻醉无差异(OR,1.44;95%CI,0.87 - 2.38;P = 0.16;I² = 0%)。在下颌阻滞麻醉成功后用于补充浸润时,阿替卡因比利多卡因显著更有效(OR,3.55;95%CI,1.97 - 6.39;P < 0.0001;I² = 9%)。没有不良事件的报告。

结论

这项对双盲随机临床试验的系统评价提供了一级证据,支持对有症状不可逆性牙髓炎患者使用阿替卡因。在下颌阻滞麻醉后用于补充浸润时,使用阿替卡因比利多卡因有显著优势,但单独用于下颌阻滞麻醉或上颌浸润时没有优势。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验